Jim Scibetta
Chief Executive Officer

Jim Scibetta has been Chief Executive Officer of VectorY Therapeutics since November 2024. Mr. Scibetta brings more than 20 years of executive leadership experience, building earlier stage companies focused on developing novel therapeutics for high unmet medical needs into mature biotechnology companies.

Prior to joining VectorY Therapeutics, Mr. Scibetta served as a Senior Consultant at Rock Springs Capital, a leading healthcare investment fund. He has served on numerous private and public company boards at value generating biotech companies, including CEO of Maverick Therapeutics leading to its 2021 acquisition by Takeda, President of Pacira BioSciences (Nasdaq: PCRX) during its growth from a clinical stage private company to commercial stage > $2 billion public company, and CFO of BioEnvision (Nasdaq: BIVN), instrumental in its sale to Genzyme. He has also served on the Boards and in executive positions at Matinas BioPharma, ImmuneID and Aquestive Therapeutics.

Mr. Scibetta received his Bachelor's degree from Wake Forest University and an MBA from the University of Michigan. Prior to his biotech company-building career, Mr. Scibetta spent 13 years in healthcare investment banking at Shattuck Hammond Partners and Paine Webber. He has an MBA from the University of Michigan.